Advertisement

Advertisement
Survivorship

Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer

With the pediatric cancer survival rate exceeding 80%, “we can reasonably suspect that most of these children will survive more than 5 years from their diagnosis and then go on to puberty,” when they may have to deal with the consequences of cancer treatment, according to Rebecca Flyckt, MD, Division Director, Reproductive Endocrinology and Infertility, University Hospitals of Cleveland, Case Western Reserve University. For girls, these consequences can include damage to the ovaries and infertility. Ovarian tissue cryopreservation prior to cancer treatment and then later reimplantation may be the best way to preserve fertility.

Leukemia

ADMIRAL Trial: More Than Standard Chemotherapy Needed for FLT3-Mutant Advanced AML

The important ADMIRAL trial, reported by Perl et al in The New England Journal of Medicine and reviewed in this issue of The ASCO Post, shows the efficacy of a specific FLT3 inhibitor in patients with advanced acute myeloid leukemia (AML) and enhances the era of personalized medicine in leukemia.

Issues in Oncology
Breast Cancer
Survivorship
Prostate Cancer

Elevations in Cancer Incidence Among Responders to the WTC Site After the September 11 Attacks

We’ll start off this week on The ASCO Post Podcast by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes...

 

 

 


Advertisement
Pancreatic Cancer

Olaparib as Maintenance Therapy for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma

On December 27, 2019, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib was approved for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma, as detected by a U.S. Food and Drug Administration (FDA)-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. The FDA also approved the BRACAnalysis CDx test as a companion diagnostic for the selection of patients with pancreatic cancer for treatment with olaparib based upon the identification of deleterious or suspected deleterious germline mutations in BRCA1 or BRCA2.

Breast Cancer

Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer

A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with triple-negative breast cancer. However, the addition of the RANK ligand inhibitor denosumab to neoadjuvant chemotherapy had no impact on pathologic complete response. These preliminary findings of the pathologic complete response rates in the GeparX study were presented at the 2019 San Antonio Breast Cancer Symposium.

Advertisement




More Top Stories

Multiple Myeloma
Sarcoma
Immunotherapy

Edward A. Stadtmauer, MD, on Advanced Multiple Myeloma and Sarcoma: First-in-Human Assessment of CRISPR-Edited T Cells

Breast Cancer

FDA Pooled Analysis of CDK4/6 Inhibitor Treatment for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Jennifer J. Gao, MD, and colleagues found that the magnitude of progression-free survival benefit with the addition of a cyclin-dependent kinase (CDK) 4/6 inhibitor to endocrine therapy in women with...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Lung Cancer
Immunotherapy

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Prostate Cancer

Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer

Researchers at have developed a method based on artificial intelligence (AI) for the histopathologic diagnosis and grading of prostate cancer. The study, published by Ström et al in The Lancet Oncology, showed that the AI system can be trained to detect and grade prostate cancer from needle biopsy...

Skin Cancer

Does Weight-Loss Surgery Lower the Risk of Malignant Melanoma?

Bariatric surgery is associated with a distinct reduction in skin cancer risk, according to findings published by Taube et al in JAMA Dermatology. This finding further substantiates the connection between weight loss and malignant skin cancer. “This [study] provides further evidence for a...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Milan Radovich, PhD, on ctDNA After Neoadjuvant Chemotherapy and Recurrence in Triple-Negative Breast Cancer

Sarcoma

Pathologic Fracture and Prognosis in Adult and Pediatric Patients With High-Grade Osteosarcoma

In a study reported in the Journal of Clinical Oncology, Kelley et al found that pathologic fracture was associated with poorer overall survival among adult—but not pediatric—patients with primary central high-grade osteosarcoma of the extremities. Study Details The study involved retrospective...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...